Table 2 Clinical characteristics and therapeutic results between LEV group and Other ASMs group
|  | LEV group (n = 16) | Other AEDs group (n = 23) | Statistic | P |
|---|---|---|---|---|
Gender (male/female) | 10/6 | 11/12 | - | 0.516# |
Onset age [M (P25 ~ P75), m] | 5.25 (3.25 ~ 6.00) | 4.00 (4.00 ~ 5.00) | Z = 1.174* | 0.240 |
Distribution of variation [n (%)] | Â | Â | Â | Â |
Microdeletion | 5 (31.25%) | 2 (8.70%) | χ2 = 3.542# | 0.315 |
Duplication | 7 (43.75%) | 15 (65.22%) | ||
Missense | 1 (6.25%) | 2 (8.70%) | ||
Deletion | 3 (18.75%) | 4 (17.39%) | ||
EEG | Â | Â | Â | Â |
Normal | 3 (18.75%) | 4 (17.39%) | χ2  = 0.243# | 1.000# |
MFD | 4 (25.00%) | 5 (21.74%) | ||
FD | 9 (56.25%) | 14 (60.87%) | ||
Epileptic phenotype | Â | Â | Â | Â |
Focal | 3 (18.75%) | 5 (21.74%) | χ2  = 0.209# | 1.000# |
FBTCS | 11 (68.75%) | 15 (65.22%) | ||
Focal + FBTCS | 2 (12.50%) | 3 (13.04%) | ||
Therapeutic effect [n (%)] | Â | Â | Â | Â |
Effective | 2 (12.50%) | 22 (95.65%) | χ2  = 29.541# | 0.000 |
Ineffective | 5 (31.25%) | 1 (4.35%) | ||
Aggravated | 9 (56.25%) | 0 | ||
Effective time∆ [M (P25 ~ P75),d] | 15.00 (9.50 ~ 45.00) | 1.00 (1.00 ~ 1.00) | Z = 4.912* | 0.000 |